CERTIFICATE OF ANALYSIS

PuriLab Analytical

Tirzepatide 30 mg

TZ-2026-067 Lot 20-10-02 Analyzed November 14, 2026

TIMELINE

ORDERED
October 25, 2026

RECEIVED
November 13, 2026

ANALYZED
November 14, 2026

SAMPLE

NAME
Tirzepatide 30 mg

EXPECTED
Tirzepatide

AMOUNT
1 vial, lyophilized powder

TESTING

CLIENT
SALT Peptides

TEST TYPE
Content & purity

METHOD
HPLC-UV

CONTENT, HOW MUCH IS IN IT

30.50 mg

Label claim: 30 mg


PURITY, HOW CLEAN IT IS

99.9%

Measured, not estimated. Purity is calculated from the full chromatogram shown above, and no impurity peaks were detected above the reporting threshold.

CHROMATOGRAM

HPLC-UV



● 19.01 min, Tirzepatide, 99.9%

ANALYST COMMENTS

White lyophilized powder, green-cap vial, received sealed.

ANALYST SIGNATURE

Max Barrett
Lab Director, PuriLab Analytical
Analysis date: November 14, 2026

VERIFICATION CODE
TZ-31B2-QGF9
Verify at purilab.org/verify/TZ-31B2-QGF9

SCAN TO VERIFY

TZ-31B2-QGF9

Results apply solely to the sample as received and are not representative of any larger lot, batch, or production run. Findings are limited to the analytes stated above. PuriLab Analytical is an independent testing laboratory, is not CLIA certified or ISO 17025 accredited, does not sell or distribute any substance, and makes no representation as to the safety, legality, or fitness of any material for any use.